Cargando…
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
The fusion oncoprotein Bcr-Abl is an aberrant tyrosine kinase responsible for chronic myeloid leukemia and acute lymphoblastic leukemia. The auto-inhibition regulatory module observed in the progenitor kinase c-Abl is lost in the aberrant Bcr-Abl, because of the lack of the N-myristoylated cap able...
Autores principales: | Carofiglio, Francesca, Trisciuzzi, Daniela, Gambacorta, Nicola, Leonetti, Francesco, Stefanachi, Angela, Nicolotti, Orazio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570842/ https://www.ncbi.nlm.nih.gov/pubmed/32937901 http://dx.doi.org/10.3390/molecules25184210 |
Ejemplares similares
-
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020) -
Mathematics anxiety—where are we and where shall we go?
por: Cipora, Krzysztof, et al.
Publicado: (2022) -
Natural Products and Synthetic Biology: Where We Are and Where We Need To Go
por: Kunakom, Sylvia, et al.
Publicado: (2019) -
Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?
por: Ashburner, Jeffrey M., et al.
Publicado: (2021) -
50 Years of Women in Cell Biology: Where have we been? Where are we going?
por: Masur, Sandra K., et al.
Publicado: (2021)